AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

Justin Smith has given his Buy rating due to a combination of factors that highlight AstraZeneca’s potential amidst current challenges. Despite concerns surrounding an investigation in China, Smith ...

AstraZeneca's shares have fallen more than 8% on speculation about an anti-corruption probe in China, its second-largest market, wiping around $14 billion off its value. The sell-off appears to ...

Also in today’s newsletter, US regulators plan to investigate Microsoft’s cloud business, and Disney-Reliance Indian media giant says TV ‘is not dead’ ...

The headline equity benchmarks continued their downward trend on Thursday, marking the sixth consecutive day of losses. The Nifty 50 index settled below the 23,550 mark, having reached a days high of ...

AstraZeneca PLC Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AZN ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

The CNS Summit Digital Innovation Index, developed in conjunction with IDEA Pharma, was revealed at the CNS Summit annual meeting on November 13. The index evaluates and ranks biopharma companies' ...

PM Narendra Modi will receive Dominica's top honour at India-CARICOM Summit in Guyana for COVID-19 aid and strong bilateral ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

All 11 sectors are in the green for the year. The optimism comes as the economy is likely to continue to grow because the ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...